| Item Type | Name |
|
Concept
|
Anemia, Macrocytic
|
|
Concept
|
Anemia, Refractory, with Excess of Blasts
|
|
Concept
|
Anemia, Refractory
|
|
Concept
|
Anemia
|
|
Concept
|
Anemia, Sideroblastic
|
|
Concept
|
Anemia, Aplastic
|
|
Academic Article
|
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
|
|
Academic Article
|
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
|
|
Academic Article
|
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
|
|
Academic Article
|
A prognostic score for patients with lower risk myelodysplastic syndrome.
|
|
Academic Article
|
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
|
|
Academic Article
|
Myelodysplastic syndromes: clinical practice guidelines in oncology.
|
|
Academic Article
|
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
|
Academic Article
|
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
|
|
Academic Article
|
Current and future management options for myelodysplastic syndromes.
|
|
Academic Article
|
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.
|
|
Academic Article
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
|
Academic Article
|
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.
|
|
Academic Article
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
|
Academic Article
|
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
|
|
Academic Article
|
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
|
Academic Article
|
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
|
|
Academic Article
|
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
|
|
Academic Article
|
Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
|
|
Academic Article
|
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
|
|
Academic Article
|
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
|
|
Academic Article
|
Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria.
|
|
Academic Article
|
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.
|
|
Academic Article
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
|
|
Academic Article
|
MDS/MPN-RS-T justified inclusion as a unique disease entity?
|
|
Academic Article
|
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
|
|
Academic Article
|
Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
|
|
Academic Article
|
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
|
|
Academic Article
|
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
|
|
Academic Article
|
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
|
|
Academic Article
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
|
|
Academic Article
|
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
|